Regulatory Roadmap 2026-2028 for Medical Devices in Egypt and Manufacturer Priorities

1. Key takeaways

Egypt’s regulatory variables over the next three years concentrate on four lines: guideline system iteration (five guidelines revised together in September 2025, the vigilance guideline first issued in November 2025, and the UDI revision in May 2026); identification system implementation (UDI data obligations already in force, with the mandatory timeline for label carriers pending announcement); regulatory maturity upgrade (ML3 reassessment and the ML4 target); and localization policy (the April 16, 2026 CE facilitation announcement). For Chinese manufacturers, the three priority tasks are: first, resolving the route to obtaining a reference-country FSC; second, rebuilding dossiers and SOPs against the 2025/2026 current versions; and third, establishing a vigilance and periodic reporting system.

2. Legal basis

The roadmap rests on the current EDREX guideline versions, the UDI guideline and the sequence of EDA applicant notices.

3. Expert insights

Insight 1: the certain variable for 2026 is UDI, and the uncertain variable is its label implementation timeline.

EDREX: GL.CAMD.005 Version 02/2026 was published and became applicable in May 2026. Its Chapter 3 import data obligations, namely providing UDI-PI, destination and batch quantity for each DI, are already in force. Chapter 4 states that the implementation timeline for placing UDI carriers on device labels and direct marking on reusable devices will be announced separately once market readiness is achieved. The correct posture for companies is to build the data first and wait for the announcement before changing labels.

Insight 2: the September 2025 revision round was a watershed, and SOPs based on older versions are obsolete.

GL.CAMD.002, GL.CAMD.09, GL.CAMD.007 and GL.CAMD.008 rose to Version 2 in the same round, GL.CAMD.003 rose to Version 3, all effective in September 2025; GL.CAP.Care.040 was first issued as a standalone guideline in November 2025. Dossiers and internal SOPs prepared under the 2024 or earlier versions must be re-verified against the current versions.

Insight 3: the biggest variable for 2027 and 2028 is whether the ML3 reassessment brings the device side into evaluation.

In the WHO list (as of August 2026), the ML3 scope of the Egyptian EDA covers medicines and vaccines and excludes medical devices. The EDA is advancing ML3 reassessment and the ML4 target. Once the device side enters the evaluation horizon, Egyptian device rules are likely to move closer to the IMDRF system, placing companies that build early on internationally accepted frameworks (ISO 13485, ISO 14971, ISO 10993, ISO 20417 and UDI) in an advantaged position.

Insight 4: localization policy will keep intensifying, and the relative cost of the import pathway will rise.

The April 16, 2026 CE facilitation announcement, the F-Toll mechanism in Annex 3, the 2-year rectification period in Section 4.2.2, and the export-only certificates in Section 9 together tilt the field toward local manufacturing. At the meeting on September 13, 2026, the Prime Minister again emphasised support for localization and export expansion. Chinese manufacturers should evaluate localized production as a mid-term option rather than defaulting to pure importing.

Insight 5: the first priority for Chinese manufacturers is the reference-country FSC, because it determines the pathway shape.

China is not on the 37-country reference country list. Consequently, non-sterile Class IIb and III imported devices must submit a reference-country FSC (Section 4.2.1); Class IIb and III devices are assessed by a dedicated scientific committee (Section 5, first scenario); and re-registration also goes before the committee unless the four exemption conditions are met. Obtaining a reference-country FSC, for example by achieving first market placement in any reference country, fundamentally changes the pathway length and data volume. This is the highest-return task Chinese manufacturers can undertake for Egypt.

Insight 6: the second priority is version alignment of dossiers and SOPs.

Item-by-item review should cover: certificate remaining validity of at least 3 months or a 5-year validity; ISO 13485:2016 covering the device categories with a certification body holding an IAF recognition chain; completeness of the ten items of the Declaration of Conformity; the CE annex pathway matching the classification; technical documentation on legal manufacturer letterhead with signatures and stamps; Arabic and English label fields checked against the four categories of the 2022 labelling guideline; and stability study conditions compliant with climatic zone IVa.

Insight 7: the third priority is the vigilance and periodic reporting system.

The three-tier timeframes of 2/10/15 calendar days run from establishment of the causal relationship and apply only to incidents in Egypt; the MIR (Annex 7), UIR (Annex 2) and PSR (Annex 9) are three separate forms; PMSR and PSUR are scheduled by classification (annually / every 2 years / every 3 years); and global recalls, FSN and FSCA must be reported. This system must be established at the registration stage through commitment letters, not retrofitted after market placement.

4. Practical recommendations

2026: first, complete the re-verification of all marketed product dossiers against the September / November 2025 current versions; second, establish the UDI data ledger (DI, PI, destination, batch quantity); third, establish the vigilance SOP with a 2/10/15 calendar day timing mechanism; fourth, start the feasibility work on the reference-country FSC route.

2027: first, track the announcement of the UDI label carrier implementation timeline and finalise the label changeover plan; second, establish the PMSR / PSUR reporting calendar by classification; third, re-verify certificate validity and the IAF recognition chain; fourth, track ML3 reassessment progress and any move toward device-side evaluation.

2028: first, evaluate the feasibility of localized production in Egypt (including F-Toll and CE-holding factories); second, re-verify the expiry ledger for the 10-year registration licences and the re-registration windows; third, establish long-term data accumulation for real-time stability studies; fourth, align early with the international standards system in the direction of ML4.

The three priority tasks for Chinese manufacturers: first, feasibility work on the reference-country FSC route, which determines the pathway shape; second, version alignment of dossiers and SOPs, which determines acceptance efficiency; third, building the vigilance and periodic reporting system, which determines long-term licence holder standing.

5. Verification checklist

• □ All marketed product dossiers have been re-verified against the 2025-09 / 2025-11 current versions
• □ The UDI data ledger is established, with the label changeover plan awaiting the announcement
• □ The vigilance SOP and the 2/10/15 calendar day timing mechanism are established
• □ Templates for the three forms MIR / UIR / PSR are configured
• □ The PMSR / PSUR reporting calendar is scheduled by classification (annually / every 2 years / every 3 years)
• □ The route for obtaining the reference-country FSC has completed feasibility work
• □ Certificate validity (at least 3 months or 5 years) and the IAF recognition chain have been re-verified
• □ The expiry ledger for the 10-year registration licences and the re-registration windows are established
• □ The feasibility of localized production in Egypt has been evaluated

Regulatory information verified as of October 29, 2026. The roadmap in this article is based on the current EDREX guideline versions (GL.CAMD.002 v2, GL.CAMD.003 v3, GL.CAMD.007 v2, GL.CAMD.09 v2, GL.CAP.Care.040 v1, GL.CAMD.005 02/2026), EDA website announcements (including 2026-04-16), and the World Health Organization list (as of August 2026).

• Egypt local support: GRZAN assists manufacturers from the Chinese mainland and overseas with EDA medical device registration, import approval and variation applications, including registration applicant pathway design (importing company, local factory, or Scientific Office), preparation for Scientific Committee evaluation, demonstration of free sale certificate routes from reference countries, Arabic labelling and instructions-for-use localization, and the setup of vigilance and periodic reporting systems.
• Service capabilities: product classification and risk grading (devices Class I–III, IVD Class A–D), registration and re-registration, applicability assessment for system registration and bundled registration, three-way variation classification, import approval and annual import plans, and support for vigilance reporting and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.